Neurology

Clinical

Pediatric epilepsy; drug-resistant epilepsy; epilepsy surgery; electroencephalography (EEG); electrocorticography (ECoG)

Research

Electrocortical stimulation for functional mapping; clinical neuropharmacology

Biography

Dr. Aungaroon received her medical degree, first-class honors, from Mahidol University, Ramathibodi Hospital, in Bangkok, Thailand. She completed her residency in pediatrics at Ramathibodi Hospital. Dr. Aungaroon then completed her residency in pediatric neurology and her fellowship in pediatric epilepsy at Cincinnati Children’s Hospital Medical Center in Cincinnati, OH.

In addition to direct patient care, Dr. Aungaroon has strong interests in clinical epilepsy research including medical and surgical treatment for children with epilepsy. She is currently conducting a study aimed at developing a better understanding of electrocortical stimulation for language and motor mapping in children undergoing epilepsy surgery. She is also conducting a study to explore the utility of SISCOM (Subtraction Ictal SPECT Co-registered to MRI) in evaluating epilepsy surgery planning in children. Finally, Dr. Aungaroon is interested in clinical neuropharmacology studies in pediatric epilepsy.

MD: First-class honors, Faculty of Medicine, Mahidol University, Ramathibodi Hospital, Bangkok, Thailand, 2007.

Residency: Pediatrics, Faculty of Medicine, Mahidol University, Ramathibodi Hospital, Bangkok, Thailand, 2011.

Residency: Pediatric Neurology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2014.

Fellowship: Pediatric Epilepsy, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2016.

Aungaroon G, Hallinan B, Jain P, Horn PS, Spaeth C, Arya R. Correlation Among Genotype, Phenotype, and Histology in Neuronal Ceroid Lipofuscinoses: An Individual Patient Data Meta-Analysis. Pediatr Neurol. 2016 Jul;60:42-48.e4.

Anna Weber Byars, PhD, ABPP-Cn Pediatric Neuropsychologist, Division of Neurology

is focused on neuropsychological and behavioral aspects of epilepsy. She also collaborates with researchers in the Imaging Research Center on studies of cognitive development as well as clinicians conducting clinical trials in genetic diseases.

513-636-4222 anna.byars@cchmc.org

Jamie K. Capal, MD Neurodevelopmental and Autism Specialist, Division of Neurology

has research interests focusing on children with autism spectrum disorders and related neurodevelopmental conditions. Current research projects include understanding the cognitive, behavioral, and language aspects of children with autism spectrum disorders and abnormal EEG but without concurrent clinical seizures. She is also involved in the Tuberous Sclerosis Clinic at Cincinnati Children’s Hospital Medical Center and related research projects.

513-636-4222 jamie.capal@cchmc.org

High Res

Jamie K. Capal, MD

Neurodevelopmental and Autism Specialist, Division of Neurology

Academic Affiliations

Assistant Professor, UC Department of Pediatrics

Phone 513-636-4222

Email jamie.capal@cchmc.org

Show All

Clinical

Child neurology; developmental pediatrics; autism; tuberous sclerosis

Research

Autism spectrum disorders; tuberous sclerosis

Biography

Dr. Capal’s clinical and research interests focus on children with autism spectrum disorders and related neurodevelopmental conditions. Current research projects include understanding the cognitive, behavioral, and language aspects of children with autism spectrum disorders and abnormal EEG but not always with concurrent clinical seizures. A natural extension of her research has led to interest in tuberous sclerosis complex (TSC), where autism, abnormal EEG, and seizures are frequent and interdependent. The genetic and molecular basis of TSC is well established, which provides an ideal platform for further investigation into the underlying mechanisms responsible and, in turn, discover new molecular-based targeted therapies. The TSC Clinic at Cincinnati Children’s Hospital Medical Center is the largest of its kind in the world, providing comprehensive, multidisciplinary clinical care to TSC patients of any age. This work led efforts that resulted in the first ever FDA-approved medical therapy for TSC in 2010 using the mTOR inhibitor everolimus. The long-term goal is to refine and apply these and next-generation therapies for patients with TSC.

BA: Biology with honors, Ithaca College, Ithaca, NY, 2002.

MD: Albany Medical College, Albany, NY, 2002.

Internship: Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2006-2007.

Residency: Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2007-2008.

Resident/Fellow: Pediatric Neurodevelopmental Disabilities, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2008-1012.

Fountain-Capal JK, Holland KD, Gilbert DL, Hallinan BE. When Should Clinicians Order Genetic Testing for Dravet Syndrome? Pediatr Neurol. 2011 Nov;45(5):319-23.

James (Jim) J. Collins, MD, PhD Director, Congenital Myopathy Disorders

focuses on improving outcomes in neuromuscular disorders. He is particularly interested in individuals affected with congenital muscular dystrophy. Research focuses on the development of common data elements, outcome measures and biomarker discovery in preparation for future clinical therapeutic trials.

james.collins@cchmc.org

High Res

James (Jim) J. Collins, MD, PhD

Director, Congenital Myopathy Disorders

Academic Affiliations

Assistant Professor, UC Department of Pediatrics

Fax 513-636-1888

Email james.collins@cchmc.org

Show All

Congenital muscular dystrophies; merosin-deficient congenital muscular dystrophy

Biography

James Collins MD, PhD, obtained specialty training in neuromuscular disorders at the Institute of Human Genetics, Centre for Life, University of Newcastle, Newcastle, UK, in the last months of his residency training. He was then appointed assistant professor at Cincinnati Children’s Hospital Medical Center within the UC Department of Pediatrics where he follows patients in general Neurology and in the Comprehensive Neuromuscular Center.

PhD: Kent State University, Kent, OH, 2000.

MD: University of Cincinnati, Cincinnati, OH, 2004.

Residency: Pediatric Neurology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2009.

Certification: Child Neurology, 2009.

Collins J and Bönneman CG. Congenital Muscular Dystrophies: Toward Molecular Therapeutic Intervention. Current Neurology and Neuroscience Reports. 2010 Mar;10(2):83-91.

Collins J, Tang LY, Dimmock D, Morehart P, Bove K, Wong LJC, Wong B. Progressive myofiber changes of a childhood mitochondrial DNA depletion syndrome with a novel Thymidine Kinase 2 gene mutation. Neuromuscul Disord. 2009;19:784-787.

Allen D. DeSena, MD, MPH Pediatric Neuroimmunology Specialist, Division of Neurology

does clinical research as it pertains to the emerging field of pediatric neuroimmunology. He has interest in determining best practices for patients in the acute and subacute period for neuroimmunologic conditions. He also has interest in endeavors to better manage pediatric patients with MS, NMO, transverse myelitis, and autoimmune encephalitis, such as anti-NMDA receptor antibody encephalitis.

513-636-4222 allen.desena@cchmc.org

Allen D. DeSena, MD, MPH

Pediatric Neuroimmunology Specialist, Division of Neurology

Academic Affiliation

Assistant Professor

Phone 513-636-4222

Email allen.desena@cchmc.org

Show All

Clinical

Multiple sclerosis; transverse myelitis; neuromyelitis optica; autoimmune encephalitis; anti-NMDA receptor antibody encephalitis; opsoclonus-myoclonus syndrome; antibody-mediated central nervous system disorders; CICU

Research

Clinical research focusing on therapeutics of the following: multiple sclerosis, transverse myelitis, neuromyelitis optica, autoimmune encephalitis, anti-NMDA receptor antibody encephalitis, opsoclonus-myoclonus syndrome, antibody-mediated central nervous system disorders.

MD: Loyola-Stritch School of Medicine, Maywood, IL, 2006.

Residency: General Pediatrics, Tulane-Ochsner General Pediatrics Residency, New Orleans, LA, 2006-2009.

Residency: Child Neurology Residency, UT Southwestern Medical Center, Dallas, TX, 2009-2012.

Fellowship: Pediatric and Adult Neuroimmunology Fellowship, UT Southwestern Medical Center, 2012-2014.

Certification: General Pediatrics, 2009; Neurology with special qualifications in Child Neurology, 2012.

DeSena AD, Greenberg BM, Graves D. "Light switch" mental status changes and irritable insomnia are two particularly salient features of anti-NMDA receptor antibody encephalitis. Pediatr Neurol. 2014 Jul;51(1):151-3.

DeSena AD, Greenberg BM, Graves D. Three Phenotypes of Anti-N-Methyl-d-Aspartate Receptor Antibody Encephalitis in Children: Prevalence of Symptoms and Prognosis. Pediatr Neurol. 2014 May 29.

DeSena A, Graves D, Morriss MC, Greenberg BM. Transverse myelitis plus syndrome and acute disseminated encephalomyelitis plus syndrome: a case series of 5 children. JAMA Neurol. 2014 May;71(5):624-9.

Desena A, Graves D, Warnack W, Greenberg BM. Herpes simplex encephalitis as a potential cause of anti-N-methyl-D-aspartate receptor antibody encephalitis: report of 2 cases. JAMA Neurol. 2014 Mar;71(3):344-6.

David Neal Franz, MD Founding Director, Tuberous Sclerosis Clinic

focuses on using a combination of clinical investigation, basic science research and innovative social programs to improve clinical care for patients with tuberous sclerosis complex (TSC). He and his team are active in human clinical trials with mTOR inhibitors to treat subependymal giant cell astrocytoma (SEGA), epilepsy and cognitive disabilities that occur in patients with TSC. In the laboratory, he is focused on understanding the mechanisms through which mTOR dysregulation in the brain contributes to TSC disease pathogenesis and developing suitable biomarkers capable of predicting disease severity and treatment response.

513-636-4222 david.franz@cchmc.org

High Res

David Neal Franz, MD

Founding Director, Tuberous Sclerosis Clinic

Associate Director of Clinical Affairs, Division of Neurology

Academic Affiliations

Professor, UC Department of Pediatrics

Phone 513-636-4222

Fax 513-636-1888

Email david.franz@cchmc.org

Show All

Clinical Interests

Tuberous sclerosis (adults and children); neuropharmacology; neurocutaneous disorders; general pediatric neurology

Biography

David Neal Franz, MD, was born and raised in Dayton, Ohio. He received his undergraduate degree in history and literature from Earlham College in Richmond, Indiana.

After completing his training, he served as assistant professor of neurology and pediatrics at Wright State University before returning to Cincinnati Children's Hospital Medical Center.

He established the Cincinnati Tuberous Sclerosis Clinic in 1993, to assist in the medical care of patients who have or are suspected of having tuberous sclerosis. The purpose of the clinic is not to replace care from the child's pediatrician or family physician, but to assist the primary care physician in dealing with those aspects unique to tuberous sclerosis that affect the child's health or development. The basis of the clinic is the realization that people with tuberous sclerosis are different from other individuals who have epilepsy, learning disabilities, behavior problems, etc.

For too long, the unique problems found in this disease have been lumped together with similar disorders, despite the fact that research has shown that disorders of the brain, heart, kidney, and other organs in tuberous sclerosis are quite different.

MD: Ohio State University College of Medicine, Columbus, OH, 1985.

Residency: Wright State University Affiliated Hospitals, Dayton, OH.

Fellowship: Children's Hospital Medical Center, Cincinnati, OH.

Certification: Pediatrics, 1990, 2014; Neurology with special competence in child neurology, 1992.

Tyburczy ME, Dies KA, Glass J, Camposano S, Chekaluk Y, Thorner AR, Lin L, Krueger D, Franz DN, Thiele EA, Sahin M, Kwiatkowski DJ. Mosaic and Intronic Mutations in TSC1/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing. PLoS Genet. 2015 Nov 5;11(11):e1005637.

Franz DN, Agricola K, Mays M, Tudor C, Care MM, Holland-Bouley K, Berkowitz N, Miao S, Peyrard S, Krueger DA. Everolimus for subependymal giant cell astrocytoma: 5-year final analysis. Ann Neurol. 2015 Sep 18.

Arya R, Tenney JR, Horn PS, Greiner HM, Holland KD, Leach JL, Gelfand MJ, Rozhkov L, Fujiwara H, Rose DF, Franz DN, Mangano FT. Long-term outcomes of resective epilepsy surgery after invasive presurgical evaluation in children with tuberous sclerosis complex and bilateral multiple lesions. J Neurosurg Pediatr. 2015 Jan;15(1):26-33.

Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Berkowitz N, Anak O, Niolat J, Jozwiak S. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. Lancet Oncol. 2014 Dec;15(13):1513-20.

Kingswood JC, Jozwiak S, Belousova ED, Frost MD, Kuperman RA, Bebin EM, Korf BR, Flamini JR, Kohrman MH, Sparagana SP, Wu JY, Brechenmacher T, Stein K, Berkowitz N, Bissler JJ, Franz DN. The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1. Nephrol Dial Transplant. 2014 Jun;29(6):1203-10.

Franz DN. Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex. Biologics. 2013;7:211-21.

Roth J, Roach ES, Bartels U, Jóźwiak S, Koenig MK, Weiner HL, Franz DN, Wang HZ. Subependymal giant cell astrocytoma: diagnosis, screening, and treatment. Recommendations from the International Tuberous Sclerosis Complex Consensus Conference 2012. Pediatr Neurol. 2013 Dec;49(6):439-44.

Krueger DA, Northrup H, Franz DN; International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013 Oct;49(4):255-65.

Wirrell EC, Laux L, Franz DN, Sullivan J, Saneto RP, Morse RP, Devinsky O, Chugani H, Hernandez A, Hamiwka L, Mikati MA, Valencia I, Le Guern ME, Chancharme L, de Menezes MS. Stiripentol in Dravet syndrome: results of a retrospective U.S. study. Epilepsia. 2013 Sep;54(9):1595-604.

Northrup H, Krueger DA; International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013 Oct;49(4):243-54.

Donald L. Gilbert, MD, MS Director, Movement Disorder Clinic and Tourette's Syndrome Clinic

is interested in motor control in children with Tourette syndrome, attention deficit hyperactivity disorder, and other conditions that affect movement. To do this, the team’s laboratory uses transcranial magnetic stimulation (TMS) to measure signals in the motor control areas of the brain and measures motor coordination in the hands. The team is also using the TMS magnet to try to improve how the brain controls speech in adults who have suffered strokes; they hope to bring this type of treatment to children in the future. The team also does trials of new medications for Tourette's syndrome.
Visit the Gilbert / Wu / Pedapati Lab.

513-636-4222 donald.gilbert@cchmc.org

High Res

Donald L. Gilbert, MD, MS

Director, Movement Disorder Clinic and Tourette's Syndrome Clinic

Academic Affiliations

Professor, UC Department of Pediatrics

Phone 513-636-4222

Fax 513-636-3980

Email donald.gilbert@cchmc.org

Show All

Visit the Gilbert / Wu / Pedapati Lab.

Clinical

Movement disorders; Tourette's syndrome; Sydenham's chorea; kernicterus; dystonia; ataxia; clinical research; transcranial magnetic stimulation

Research

Clinical trials in Tourette's syndrome and associated ADHD; epidemiology of Tourette's syndrome and PANDAS; clinical effectiveness of multi-drug treatments in Tourette's syndrome; transcranial magnetic stimulation in Tourette's syndrome and pediatric movement disorders; functional neurosurgery for pediatric dystonia

Biography

Donald Gilbert, MD, earned his Bachelor of Arts at Princeton University, where he majored in philosophy. He subsequently earned his MD at the University of Michigan and spent a year at the National Institutes of Health as a Howard Hughes Medical Institute Research Scholar. Dr. Gilbert did his pediatrics and neurology training at John Hopkins in Baltimore and is board certified in neurology with special competence in child neurology. Dr. Gilbert has an MS in clinical research design and statistical analysis from the University of Michigan.

At Cincinnati Children's, Dr. Gilbert directs the Movement Disorders and Tourette's Syndrome Clinics, which specialize in evaluation and pharmacologic treatment of tics, chorea, tremor, dystonia, stereotypies, ataxia, and other movement disorders. Dr. Gilbert directs or participates in a number of single and multi-center studies into causes and treatments of Tourette's syndrome. Dr. Gilbert directs the Transcranial Magnetic Stimulation Laboratory at Cincinnati Children's.

BA: Princeton University, Princeton, NJ, 1987.

MD: University of Michigan School of Medicine, Ann Arbor, MI, 1993.

MS: University of Michigan, Ann Arbor, MI, 2003.

Pediatrics, Child Neurology Residency: Johns Hopkins School of Medicine, Baltimore, MD, 1998.

Certification: Board Certified in Neurology with Special Competence in Child Neurology, 2010; Board eligible in Pediatrics.

Appointment: Professor of Pediatric Neurology.

Hong YH, Wu SW, Pedapati EV, Horn PS, Huddleston DA, Laue CS, Gilbert DL. Safety and Tolerability of Theta Burst Stimulation versus Single and Paired Pulse Transcranial Magnetic Stimulation: A Comparative Study of 164 Pediatric Subjects. Frontiers in Neuroscience. 2015. doi: 10.3389/fnhum.2015.00029

Dietrich A, Fernandez TV, King RA, State MW, Tischfield JA, Hoekstra PJ, Heiman GA, and the TIC Genetics Collaborative Group. The Tourette International Collaborative Genetics (TIC Genetics) study, finding the genes causing Tourette Syndrome: objectives and methods. Eur Child Adolesc Psychiatry, 2014. DOI 10.1007/s00787-014-0543-x

Gilbert DL, Budman CL, Singer HS, Kurlan R, Chipkin RE. A D1 Receptor Antagonist, Ecopipam, for treatment of tics in Tourette Syndrome. Clinical Neuropharmacology, 2014. 37:26-30.

Chen TH, Wu SW, Dixon S, Shahana N, Huddleston DA, Sarvis AR, Sallee FR, Gilbert DL. Motor Cortex Physiology and Stop Signal Reaction Times as Predictors and Correlates of Atomoxetine Responses in Children with ADHD. Journal of Child Neurology, 2014. 29:1672-9. DOI: 10.1177/0883073813513333.

Wu SW, Maloney T, Gilbert DL, Dixon SG, Horn PS, Huddleston DA, Eaton K, Vannest J. Functional MRI-navigated Repetitive Transcranial Magnetic Stimulation of Supplementary Motor Area in Chronic Tic Disorders. Brain Stimulation. 2014. 7: 212-218.

Gilbert DL, Patterson MC, Pugh JA, Ridel KR, Reynolds TQ, Valencia I. Views of Recently First-Certified US Child Neurologists on Their Residency Training. Journal of Child Neurology, 2013. 28 (3): 332-339. doi 10.1177/0883073812473644.

Wu SW, Shahana N, Huddleston DA, Gilbert DL. Effects of 30 Hz Theta Burst Transcranial Magnetic Stimulation on the primary motor cortex. Journal of Neuroscience Methods, 2012; 208: 161-164.

Wu SW, Gilbert DL, Shahan N, Huddleston DA, Mostofsky SH. Transcranial Magnetic Stimulation Measures in Attention Deficit/Hyperactivity Disorder. Pediatric Neurology, 2012; 47: 177-185. Doi: 10.1016/j.pediatricneurol.2012.06.0003.

Wu SW, Shahana N, Huddleston DA, Lewis AN, Gilbert DL. Safety and Tolerability of Theta Burst Stimulation in Children. Developmental Medicine and Child Neurology. 2012, 54 (7): 636-639. Doi: 10.111/j.1469-8749.2012.04300.x.

Edden RAE, Crocetti D, Zhu H, Gilbert DL, Mostofsky SH. Reduced GABA concentration in Attention Deficit/Hyperactivity Disorder. Archives of General Psychiatry. 2012; 69: 750-753. PMID: 22752239.

Tracy A. Glauser, MD Associate Director, Cincinnati Children's Research Foundation

is director of the Comprehensive Epilepsy Center and co-director of the Genetic Pharmacology Service. His research has focused on improving the care of children with epilepsy through identifying the genetic and non-heritable factors that underlie the inter-individual variation in response to antiepileptic medications. Since 2003, he has directed the NIH-funded Childhood Absence Epilepsy trial, a 31-center, 446-patient double-blind randomized comparative trial of three commonly used antiepileptic medications focused on identifying the optimal initial therapy for children with childhood absence epilepsy and the pharmacokinetic, pharmacodynamic, and pharmacogenetic factors that impact the inter-individual response to antiepileptic therapy. Glauser and the Genetic Pharmacology Service have also developed and are testing treatment selection algorithms for epilepsy and non-epilepsy medications that incorporate genetic information and drug-drug interactions.

513-636-4222 tracy.glauser@cchmc.org

High Res

Tracy A. Glauser, MD

Associate Director, Cincinnati Children's Research Foundation

Director, Comprehensive Epilepsy Center

Co-Director, Genetic Pharmacology Service

Academic Affiliations

Professor, UC Department of Pediatrics

Phone 513-636-4222

Fax 513-636-3980

Email tracy.glauser@cchmc.org

Show All

Clinical

Epilepsy; pharmacogenetics; clinical pharmacology

Research

Clinical pharmacology; pharmacogenetics; antiepileptic clinical trials

Biography

Tracy A. Glauser, MD, is director of the Comprehensive Epilepsy Center and co-director of the Genetic Pharmacology Service at Cincinnati Children’s Hospital Medical Center and professor of pediatrics in the University of Cincinnati College of Medicine. Dr. Glauser received his medical degree, cum laude, from Jefferson Medical College in Philadelphia, PA. He completed his residency in pediatrics at the John Hopkins Hospital in Baltimore, MD, and fellowship in child neurology at The Children’s Hospital of Philadelphia, University of Pennsylvania in Philadelphia, PA. Dr. Glauser completed a National Institute of Neurological Disorders and Stroke research fellowship in pediatric neurology and was a fellow in epilepsy and electroencephalography at St. Louis Children’s Hospital, Washington University School of Medicine in St. Louis, Missouri.

Dr. Glauser has authored and co-authored more than 130 articles and book chapters, been involved with the development of six evidence-based guidelines about epilepsy therapy and given over 150 invited lectures throughout the world. He has been the principal investigator on multiple NIH grants. Currently, Dr. Glauser directs the NIH funded Childhood Absence Epilepsy clinical trial involving 32 pediatric centers around the United States. Dr. Glauser’s fields of expertise are pediatric neurology, pediatric epilepsy, clinical pharmacology and pharmacogenetics.

MD: Jefferson Medical College, Philadelphia, PA, 1985.

Residency: Johns Hopkins Hospital, Baltimore, MD.

Fellowship: St. Louis Children's Hospital, St. Louis, MO.

Certification: Pediatrics, 1990; Neurology (with special competence in child neurology), 1991.

Modi AC, Guilfoyle SM, Morita DA, Glauser TA. Development and reliability of a correction factor for parent-reported adherence to pediatric antiepileptic drug therapy. Epilepsia. 2010 Nov 18. doi: 10.1111/j.1528-1167.2010.02789.x.

Modi AC, Monahan S, Daniels D, Glauser TA. Development and validation of the Pediatric Epilepsy Medication Self-Management Questionnaire. Epilepsy Behav. 2010 May;18(1-2):94-9

Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Capparelli EV, Adamson PC; Childhood Absence Epilepsy Study Group. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med. 2010 Mar 4;362(9):790-9.

Holland KD, Monahan S, Morita D, Vartzelis G, Glauser TA. Valproate in children with newly diagnosed idiopathic generalized epilepsy. Acta Neurol Scand. 2010 Mar;121(3):149-53.

Pestian J, Spencer M, Matykiewicz P, Zhang K, Vinks AA, Glauser T. Personalizing Drug Selection Using Advanced Clinical Decision Support. Biomed Inform Insights. 2009 Jun 23;2:19-29.

Prows CA, Nick TG, Saldaña SN, Pathak S, Liu C, Zhang K, Daniels ZS, Vinks AA, Glauser TA. Drug-metabolizing enzyme genotypes and aggressive behavior treatment response in hospitalized pediatric psychiatric patients. J Child Adolesc Psychopharmacol. 2009 Aug;19(4):385-94.

Modi AC, King AS, Monahan SR, Koumoutsos JE, Morita DA, Glauser TA. Even a single seizure negatively impacts pediatric health-related quality of life. Epilepsia. 2009 Sep;50(9):2110-6.

Daniels ZS, Nick TG, Liu C, Cassedy A, Glauser TA. Obesity is a common comorbidity for pediatric patients with untreated, newly diagnosed epilepsy. Neurology. 2009 Sep 1;73(9):658-64.

Glauser TA, Sankar R; Co-chairs of the Leadership in Epilepsy, Advocacy, and Development Faculty. Core elements of epilepsy diagnosis and management: expert consensus from the Leadership in Epilepsy, Advocacy, and Development (LEAD) faculty. Curr Med Res Opin. 2008 Dec;24(12):3463-77.

Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology. 2008 May 20;70(21):1950-8.

Christina Gross, PhD Neuroscientist, Division of Neurology

studies the molecular mechanisms underlying Fragile X syndrome and other autism spectrum and epilepsy disorders. In particular, the lab is interested in neuron-specific regulation of the PI3K pathway, and in the translational regulation of potassium channels crucial for neuronal excitability. The goal is to understand how defects in these mechanisms lead to neuronal diseases, and may serve as therapeutic targets.

Visit the Gross Lab.

513-636-3493 christina.gross@cchmc.org

High Res

Christina Gross, PhD

Neuroscientist, Division of Neurology

Academic Affiliations

Assistant Professor, UC Department of Pediatrics

Phone 513-636-3493

Email christina.gross@cchmc.org

Show All

Molecular neuroscience, fragile X syndrome

Visit the Gross Lab.

Diploma in Biochemistry: Ruhr University Bochum, Germany, 2000.

PhD: Free University of Berlin, Germany, 2004.

Gross C*, Raj N, Gemma M, Amanda AG, Whyte AJ, Gibson JR, Huber KM, Gourley SL, Bassell GJ*. Selective role of the catalytic PI3K subunit p110β in impaired higher-order cognition in Fragile X syndrome. Cell reports. 2015;11:681-688. *co-corresponding authors.

Gross C*, Chia-Wei C, Kelly SM, Bhattacharya A, McBride SM, Danielson SW, Jiang MQ, Chan CB, Ye K, Gibson JR, Klann E, Jongens TA, Moberg KH, Huber KM, Bassell GJ*. Increased expression of the PI3K enhancer PIKE mediates deficits in synaptic plasticity and behavior in Fragile X syndrome. Cell reports. 2015;11:727-736. *co-corresponding authors.

Gross C, Hoffmann A, Bassell GJ, Berry-Kravis EM. Therapeutic Strategies in fragile X syndrome: from bench to bedside and back. Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics. 2015;1-25.

Sasaki Y, Gross C, Xing L, Goshima Y, Bassell GJ. Identification of axon-enriched microRNAs localized in growth cones of cortical neurons. Dev Neurobiol. 2014 Mar;74(3):397-406.

Gross C, Bassell GJ. Neuron-specific regulation of class I PI3K catalytic subunits and their dysfunction in brain disorders. Front Mol Neurosci. 2014 Feb 13;7:12.

Jakkamsetti V, Tsai N-P, Gross C, Molinaro G, Collins KA, Nicoletti F, Wang KH, Osten P, Bassell GJ, Gibson JR, Huber KM. Experience-Induced Arc/Arg3.1 Primes CA1 Pyramidal Neurons for Metabotropic Glutamate Receptor-Dependent Long-Term Synaptic Depression. Neuron. 2013 Oct 2;80(1):72-9.

Gross C, Bassell GJ. Excess Protein Synthesis in FXS Patient Lymphoblastoid Cells Can Be Rescued with a p110beta-Selective Inhibitor. Mol Med. 2012 May 9;18:336-45.

Gross C, Yao X, Pong DL, Jeromin A, Bassell GJ. Fragile X mental retardation protein regulates protein expression and mRNA translation of the potassium channel Kv4.2. J Neurosci. 2011 Apr 13;31(15):5693-8.

Muddashetty RS, Nalavadi VC, Gross C, Yao X, Xing L, Laur O, Warren ST, Bassell GJ. Reversible inhibition of PSD-95 mRNA translation by miR-125a, FMRP phosphorylation and mGluR signaling. Mol Cell. 2011 Jun 10;42(5):673-88.

Gross C, Nakamoto M, Yao X, Chan CB, Yim SY, Ye K, Warren ST, Bassell GJ. Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome. J Neurosci. 2010 Aug 11;30(32):10624-38.

Barbara E. Hallinan, MD, PhD Neurometabolic Specialist, Division of Neurology

focuses on investigating the neurochemical mechanisms responsible for the onset of epilepsy in infants, especially infantile spasms. Early diagnosis and treatment of epilepsy in this age group has the potential to improve developmental outcome. It is hoped that a better understanding of the pathogenesis of epilepsy in infants will shift the treatment paradigm from managing the clinical convulsions to correcting the underlying neurochemical pathology.

513-636-4222

Katherine D. Holland, MD, PhD Co-Director, Child Neurophysiology Lab

focuses on understanding the reasons medications fail to control seizures in certain people with epilepsy. This work includes development of clear definitions of drug response, analysis of genetic factors that predict treatment response and analyzing the neurophysiological differences between treatment responsive and treatment resistant epilepsy. The goal of this work is to predict treatment response so that care can be more individualized.

katherine.holland@cchmc.org

High Res

Katherine D. Holland, MD, PhD

Co-Director, Child Neurophysiology Lab

Epilepsy Specialist, Division of Neurology

Academic Affiliations

Associate Professor, UC Department of Pediatrics

Email katherine.holland@cchmc.org

Show All

Mechanisms of epileptogenesis

MD: Washington University, St. Louis, MO, 1991.

PhD (pharmacology): Washington University, St. Louis, MO, 1991.

Internship: Children's Hospital, Boston, MA.

Residency: St Louis Children's Hospital, St. Louis, MO.

Certification: Neurology with added qualification in pediatric neurology, 2000.

Standridge SM, Holland KD, Horn PS. Cardiac arrhythmias and ictal events within an epilepsy monitoring unit. Pediatr Neurol. 2010 Mar;42(3):201-5.

Holland KD, Monahan S, Morita D, Vartzelis G, Glauser TA. Valproate in children with newly diagnosed idiopathic generalized epilepsy. Acta Neurol Scand. 2010 Mar;121(3):149-53.

Holland KD, Kearney JA, Glauser TA, Buck G, Keddache M, Blankston JR, Glaaser IW, Kass RS, Meisler MH. Mutation of sodium channel SCN3A in a patient with cryptogenic pediatric partial epilepsy. Neurosci Lett. 2008 Mar 5;433(1):65-70.

Holland KD, Glauser TA. Response to carbamazepine in children with newly diagnosed partial onset epilepsy. Neurology. 2007 Aug 7;69(6):596-9.

Holland KD, Fleming MT, Cheek S, Moran JL, Beier DR, Meisler MH. De novo exon duplication in a new allele of mouse Glra1 (spasmodic). Genetics. 2006 Dec;174(4):2245-7.

Paul S. Horn, PhD Biostatistician, Division of Neurology

is a statistician who is part of the Division of Neurology. He works on various research projects including the data analysis of epilepsy and seizures, neuromuscular conditions, mitochondrial diseases, and migraines. His other statistical interests include robust and nonparametric methods and their application to the derivation of reference ranges.

513-803-3256 paul.horn@cchmc.org

High Res

Paul S. Horn, PhD

Biostatistician, Division of Neurology

Academic Affiliations

Professor, UC Department of Pediatrics

Phone 513-803-3256

Email paul.horn@cchmc.org

Show All

Robustness; nonparametrics; statistical computing; simulations; reference intervals.

PhD: Statistics, Princeton University, Princeton, NJ, 1981.

Hershey AD, Horn PS, Kabbouche MA, O’Brien HL, Powers SW. Genomic expression patterns in menstrually-related migraine in adolescents. Headache: The Journal of Head and Face Pain. 2012;52(1):68-79.

Slater SK, Nelson TD, Kabbouche MA, LeCates SL, Horn P, Sagers A, Manning P, Powers SW, Hershey AD. A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine. Cephalalgia. 2011;31(8):897-905.

Seo JH, Holland K, Rose D, Rozhkov L, Fujiwara H, Byars A, Arthur T, DeGrauw T, Leach JL, Gelfand MJ, Miles L, Mangano FT, Horn P, Lee KH. Multimodality imaging in the surgical treatment of children with non-lesional epilepsy. Neurology. 2011;76(1):41-48.

Pesce A, West C, Rosenthal M, West R, Crews B, Mikel C, Almazan P, Latyshev S, Horn PS. Marijuana correlates with use of other illicit drugs in a pain patient population. Pain Physician. 2010;13(3):283-287.

Sherman KE, Shire NJ, Rouster SD, Peters MG, Koziel MJ, Chung RT, Horn PS. Viral kinetics in hepatitis C or hepatitis C/humin immunodeficiency virus-infected patients. Gastroenterology. 2005;128(2):313-327.

Horn PS, Wolfe DA. A rank-based goodness-of-fit approach to testing for non-additivity in the two-way layout with no replications. Computational Statistics and Data Analysis. 2004;46(2):357-376.

Horn PS, Feng L, Li YM, Pesce AJ. The effect of outliers and non-healthy individuals on reference interval determination. Clinical Chemistry. 2001;47(12):2137-2145.

Horn PS, Pesce AJ, Copeland B. A robust approach to reference interval estimation and evaluation. Clinical Chemistry. 1998;44(3):622-631.

Horn PS. Robust quantile estimators for skewed populations. Biometrika. 1990;77(3):631-636.

Horn PS. A biweight prediction interval for random samples. Journal of the American Statistical Association. 1988;83(1):249-256.

Marielle A. Kabbouche, MD Director, Acute and Inpatient Headache Program

is interested in acute treatment of intractable migraine headache including emergency room evaluation and treatment as well as inpatient therapies. The goal is not only to identify intractable headache but being able to identify short-term as well as long-term outcome to these interventions in children and adolescents.

513-636-4222

High Res

Marielle A. Kabbouche, MD

Director, Acute and Inpatient Headache Program

Child Neurologist, Division of Neurology

Academic Affiliations

Professor, UC Department of Pediatrics

Phone 513-636-4222

Fax 513-636-1888

Show All

Clinical

Headaches; migraines; acute and inpatient treatment of intractable headache

Research

Headache; outcome studies; health improvement; clinical effectiveness

Biography

Marielle Kabbouche, MD, received her training in child neurology at Vanderbilt University School of Medicine. She moved to Cincinnati for a specialty training in pediatric headache medicine. The position was the first for a pediatric neurologist.

After her headache training, she stayed at Cincinnati Children's as faculty and an active member of the center with involvement in all academic as well as clinical and teaching aspect of pediatric headaches. Since that time, she has been proud to be part of the maturing center that gradually developed to be the largest and most academically productive pediatric headache program in the United States and worldwide. She has been a co-PI on multiple NIH grants since 2002, and has been involved in multiple pharmaceutical and clinical studies in pediatric and adolescent migraines.

Her career has been focused on acute treatment of intractable migraines in children in emergency room, as well as inpatient, settings.

As the director of the inpatient headache unit, Dr. Kabbouche was actively involved in setting an acute headache infusion center as well as an inpatient headache unit at Cincinnati Children’s Hospital Medical Center. The headache acute care unit has been very productive in the last few years, seeing about 200-300 patients/year during peak seasons. The inpatient unit opened in July of 2011 bringing specialty care to headache patients with a team of six providers, fellows, residents and nurses. This approach to intractable headache care will have a great impact on patient’s outcome.

Dr. Kabbouche has over 25 publications and a track record of numerous book chapters and peer-reviewed papers, reviews, and abstracts in the field of headache medicine. She is also an editor of a pediatric headache book.

MD: Saint Joseph University, Faculty of Medicine, Beirut, Lebanon.

Residency: Vanderbilt University Medical Center, Nashville, TN.

Fellowship: Cincinnati Children's Hospital, Cincinnati, OH.

Hershey AD, Kabbouche MA, Powers SW. Treatment of pediatric and adolescent migraine. Pediatr Ann. 2010 Jul;39(7):416-23.

Kabbouche MA, Cleves C. Evaluation and management of children and adolescents presenting with an acute setting. Semin Pediatr Neurol. 2010 Jun;17(2):105-8.

Kabbouche MA, Powers SW, Segers A, LeCates S, Manning P, Biederman S, Vaughan P, Burdine D, Hershey AD. Inpatient treatment of status migraine with dihydroergotamine in children and adolescents. Headache. 2009 Jan;49(1):106-9.

Kabbouche MA, Gilman DK. Management of migraine in adolescents. Neuropsychiatr Dis Treat. 2008 Jun;4(3):535-48.

Kabbouche MA, Linder SL. Management of migraine in children and adolescents in the emergency department and inpatient setting. Curr Pain Headache Rep. 2005 Oct;9(5):363-7.

Kabbouche MA, Linder SL. Acute treatment of pediatric headache in the emergency department and inpatient settings. Pediatr Ann. 2005 Jun;34(6):466-71.

Kabbouche MA, Powers SW, Vockell ALB, LeCates SL, Ellinor PL, Segers A, Manning P, Hershey AD. Outcome of a multidisciplinary approach of pediatric migraine at 1, 2, and 5 years. Headache. 2005;45:1298-1303.

Book Chapters

Kabbouche MA. Migraine variants. In Andrew Hershey, Scott Powers, Paul Winners and Marielle Kabbouche (Eds.) Pediatric Headache in Clinical Practice. Wiley Blackwell, 2009.

Kabbouche MA. Other primary headaches. In Andrew Hershey, Scott Powers, Paul Winners and Marielle Kabbouche (Eds.) Pediatric Headache in Clinical Practice. Wiley Blackwell, 2009.

Kabbouche MA. Emergent therapy for children and adolescent. In Andrew Hershey, Scott Powers, Paul Winners and Marielle Kabbouche (Eds.) Pediatric Headache in Clinical Practice. Wiley Blackwell, 2009.

Darren S. Kadis, PhD Neuroimaging and Magnetoencephalography Research, Division of Neurology

studies brain-behavior relationships using modern neuroimaging techniques (i.e., MRI, MEG, etc.). His research is directed at understanding the typical organization of the brain, the role of early experience on brain structure and functional representation, and the vulnerability and plasticity of the brain in the context of early neurological insult.

513-636-2577 darren.kadis@cchmc.org

High Res

Darren S. Kadis, PhD

Neuroimaging and Magnetoencephalography Research, Division of Neurology

Academic Affiliations

Assistant Professor, UC Department of Pediatrics

Phone 513-636-2577

Email darren.kadis@cchmc.org

Show All

Specialties

Neuroimaging; epilepsy; language

Biography

Dr. Kadis received his PhD through the Department of Psychology at the University of Toronto, with a distinction in neuroscience and training in clinical neuropsychology. He conducted his graduate and post-doctoral research at the Hospital for Sick Children in Toronto, gaining experience with invasive (i.e., intracarotid sodium amobarbital procedure, electrocortical stimulation mapping) and newer noninvasive (e.g., fMRI, MEG) brain mapping procedures. His research is directed at understanding the typical organization of the brain, the role of early experience on brain structure and functional representation, and the vulnerability and plasticity of the brain in the context of early neurological insult. Currently, Dr. Kadis uses MEG in concert with structural neuroimaging and neuropsychological procedures to study speech and language representation and plasticity in the brains of children.

PhD: University of Toronto, ON, Canada, 2010.

Elliott IM, Kadis DS, Lach LM, Olds J, McCleary L, Whiting S, Snyder T, Smith ML. Quality of life in young adults who underwent respective surgery for epilepsy in childhood. Epilepsia. 2012;53(9):1577-1586.

Kadis DS, Pang EW, Mills T, Taylor MJ, McAndrews MP, Smith ML. Characterizing the normal developmental trajectory of expressive language lateralization using magnetoencephalography. Journal of the International Neuropsychological Society. 2011;17(5):896-904.

Pang EW, Wang F, Malone M, Kadis DS, Donner EJ. Localization of Broca’s area using verb generation tasks in MEG: Validation against fMRI. Neuroscience Letters. 2011;490:215-219.

Smith ML, Kelly K, Kadis DS, Elliott I, Olds J, Whiting S, Snyder T. Self-reported symptoms of psychological well-being in young adults who underwent resective epilepsy surgery in childhood. Epilepsia. 2011:52(5):891-899.

Kadis DS, Kerr EN, Rutka JT, Snead III OC, Weiss SK, Smith ML. Pathology type does not predict language lateralization in children with medically intractable epilepsy. Epilepsia. 2009;50(6):1498-1504.

Kadis DS, Smith ML, Mills T, Pang EW. MEG localization of expressive language cortex in healthy children: Application to paediatric clinical populations. Down Syndrome Quarterly. 2008;10(2):5-12.

Elliott IM, Lach L, Kadis DS, Smith ML. Psychosocial outcomes in children two years after epilepsy surgery: Has anything changed? Epilepsia. 2008;49(4):634-641.

Kadis DS, Iida K, Kerr EN, Logan WJ, McAndrews MP, Ochi A, Otsubo H, Rutka JT, Snead III OC, Weiss SK, Smith ML. Intrahemispheric reorganization of language in children with medically intractable epilepsy of the left hemisphere. Journal of the International Neurological Society. 2007;13:505-516.

Kadis DS, Stollstorff M, Elliott I, Lach L, Smith ML. Cognitive and psychological predictors of everyday memory in children with intractable epilepsy. Epilepsy and Behavior. 2004;5:37-43.

Kadis DS. Shock treatment for suicidal, depressed, psychotic and schizophrenic patients. In G. Allen & Science 2000 Collective (Eds.), Communicating science – a collection by new writers (2nd ed.). Toronto: Life Rattle Press. 2004.

Darcy A. Krueger, MD, PhD Director, Tuberous Sclerosis Clinic

uses a combination of clinical investigation, basic science research and innovative social programs to improve clinical care for patients with tuberous sclerosis complex (TSC). We are active in human clinical trials with mTOR inhibitors to treat subependymal giant cell astrocytoma (SEGA), epilepsy and cognitive disabilities that occur in patients with TSC. In the laboratory, we are focused on understanding the mechanisms through which mTOR dysregulation in the brain contributes to TSC disease pathogenesis and developing suitable biomarkers capable of predicting disease severity and treatment response.

513-636-4222 krueger_darcy@cchmc.org

Diego A. Morita, MD Co-Director, New Onset Seizure Clinic

513-636-4222 diego.morita@cchmc.org

High Res

Diego A. Morita, MD

Co-Director, New Onset Seizure Clinic

Academic Affiliations

Assistant Professor, UC Department of Pediatrics

Phone 513-636-4222

Fax 513-636-1888

Email diego.morita@cchmc.org

Show All

Clinical

Epilepsy; therapeutic drug management; pharmacogenetics

Research

Clinical pharmacology; population pharmacokinetics; antiepileptic drug tolerability

Biography

Dr. Morita obtained his medical degree with honors from the University of Buenos Aires School of Medicine in Buenos Aires, Argentina. He finished a three-year residency in pediatrics at Buenos Aires British Hospital in Buenos Aires, Argentina. In 1996, he came to the United States and continued his training in pediatrics at Miami Children's Hospital in Miami, Florida.

Dr. Morita was then a resident in neurology at the University of Cincinnati, and later a fellow in child neurology at Cincinnati Children's. He completed fellowship training in clinical neurophysiology and epilepsy, and epilepsy clinical neuropharmacology, both at Cincinnati Children's.

After his fellowships, Dr. Morita opened a child neurology private practice in Buenos Aires, Argentina, and in 2005 returned and joined the faculty at Cincinnati Children's within the University of Cincinnati College of Medicine.

Dr. Morita's interests currently include the objective assessment of antiepileptic drug side effects, pharmacogenetics of antiepileptic drugs, and individualization of drug therapy.

MD: University of Buenos Aires, Buenos Aires, Argentina, 1992.

Residency: Buenos Aires British Hospital, Buenos Aires, Argentina; Miami Children's Hospital, Miami, FL; University of Cincinnati, Cincinnati, OH.

Fellowship: Child Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Clinical Neurophysiology and Epilepsy, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Epilepsy Clinical Neuropharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.

Modi AC, Guilfoyle SM, Morita DA, Glauser TA. Development and reliability of a correction factor for parent-reported adherence to pediatric antiepileptic drug therapy. Epilepsia. 2011 Feb;52(2):370-6. doi: 10.1111/j.1528-1167.2010.02789.x.

Holland KD, Monahan S, Morita D, Vartzelis G, Glauser TA. Valproate in children with newly diagnosed idiopathic generalized epilepsy. Acta Neurol Scand. 2010 Mar;121(3):149-53.

Modi AC, King AS, Monahan SR, Koumoutsos JE, Morita DA, Glauser TA. Even a single seizure negatively impacts pediatric health-related quality of life. Epilepsia. 2009 Sep;50(9):2110-6.

Modi AC, Morita DA, Glauser TA. One-month adherence in children with new-onset epilepsy: white-coat compliance does not occur. Pediatrics. 2008 Apr;121(4):e961-6.

Hope L. O'Brien, MD Program Director, Headache Medicine Education

is an adult neurologist, interested in the transition stages of chronic headache as one develops from childhood into adults, with focus on the unique aspects of headaches and its impact on late adolescents and young adults. This includes identifying modifiable features in children with migraine that will result in reduction of intractable cases as one develops.

513-636-4222 neurodesk@cchmc.org

Ernest Pedapati, MD, MS, FAAP

is the director of the Cincinnati Children's Interventional Psychiatry Research Laboratory which is a non-surgical brain stimulation research program investigating childhood neurodevelopmental and psychiatric disorders. This laboratory represents an expansion of the well-established child neurology Gilbert TMS Lab.
Visit the Gilbert / Wu / Pedapati Lab.

513-636-4611 ernest.pedapati@cchmc.org

High Res

Ernest Pedapati, MD, MS, FAAP

Academic Affiliations

Assistant Professor, N/A

UC Department of Psychiatry and Behavioral Neuroscience

Phone 513-636-4611

Email ernest.pedapati@cchmc.org

Show All

Visit the Gilbert / Wu / Pedapati Lab.

Clinical

Neurodevelopmental disorders; autism spectrum disorders; fragile X; genetic disorders; schizophrenia

Research

Transcranial magnetic stimulation; transcranial direct current stimulation; TMS; TDCS; EEG; autism; fragile x; eye tracking; electrophysiology.

Biography

Dr. Pedapati specializes in the treatment of neuropsychiatric disease associated with ASD, genetic and other neurodevelopmental disorders including interdisciplinary treatment planning and advanced medication management. Prior to his faculty appointment, he had clinical and research training under Craig Erickson, MD, and pediatric transcranial magnetic stimulation under Donald Gilbert, MD, MS.

In 2013, the PI was successful in designing and obtaining IRB approval and competitive funding for a TMS project through the American Academy of Child & Adolescent Psychiatry Pilot Research Award and currently completing the study, "Cortical Plasticity in Adolescent Depression" which attempts to use TMS to determine whether abnormal neuroplasticity can be quantified in adolescent depression.

In his final year of residency, he applied and secured a highly competitive institutional mentor career development award (Proctor Scholar) to support 90% time dedicated to independent research activities including obtaining preliminary data on TMS measures of cortical plasticity in ASD and the development of an implicit false belief task of social cognition for future TMS modulation. In addition he continues to be an active subinvestigator extensively contributing to NIH R01 project examining TMS measures of motor physiology in ADHD pioneered the use of SICI as a biomarker in ADHD and measurement of cortical plasticity in healthy youth.

MD: University of Massachusetts, Worcester, MA, 2009.

Residency: Pediatrics/Adult Psychiatry/Child Psychiatry, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.

Certification: Pediatrics, American Board of Pediatrics.

Wink LK, O’Melia AM, Shaffer RC, Pedapati E, Friedmann K, Schaefer T, Erickson CA. Intranasal Ketamine Treatment in an Adult with Autism Spectrum Disorder. J Clin. Psychiatry. 2014.

Pedapati, EV, Bateman, SC. Toddlers Requiring Pediatric Intensive Care Admission Following at-home Exposure to Buprenorphine/Naloxone. Pediatric Critical Care Med. 2011;Mar 12(2):102-7.

Rhyee SH, Pedapati EV, Thompson J. Prolonged delirium after quetiapine overdose. Pediatric Emergency Care. 2010 Oct 26;(10):754-6.

Stebbins KJ, Carr MJ, Pedapati EV, Ellis JL. Effect of olvanil on the afferent and efferent function of capsaicin-sensitive C-fibers in guinea pig airways. Eur J Pharmacol. 2003 Jun 27;471(3):205-11.

Grants

Anomalous Motor Physiology in ADHD. Subinvestigator. National Institutes of Health/National Institute of Mental Health. Sep 2012-Aug 2017. R01 MH095014.

Douglas F. Rose, MD Clinical Neurophysiologist, Division of Neurology

is interested in clinical neurophysiology of normal and abnormal brain function across multiple neuropsychiatric disorders using multiple modalities, principally electroencephalography (EEG), magnetoencephalography (MEG) and functional magnetic resonance imaging (fMRI). The normal brain function includes developmental vision, hearing, touch perception, spontaneous motor movement, attention, memory, language and pain perception. The neuropsychiatric disorders include epilepsy, cerebral palsy, stroke, tic disorders, obsessive-compulsive disorder and traumatic brain injury.

513-636-4222 douglas.rose@cchmc.org

High Res

Douglas F. Rose, MD

Clinical Neurophysiologist, Division of Neurology

Epileptologist, Division of Neurology

Academic Affiliations

Professor, UC Department of Pediatrics

Phone 513-636-4222

Fax 513-636-3980

Email douglas.rose@cchmc.org

Show All

Clinical

Epilepsy; improvement of the quality of life for children with epilepsy; studies of brain and physiology to better understand brain function

Research

Neuropharmacology; epilepsy surgery; central auditory processing; magnetoencephalography; functional cortical mapping; fMRI; SPECT; vagus nerve stimulator; ketogenic diet; language development and language disorders

Biography

Dr. Rose grew up in Cleveland, Ohio. He and his wife lived briefly in Fairborn and Dayton, Ohio when first married. Subsequently they moved to Washington, DC to study and work at the National Institutes of Health. They then moved to Albuquerque, New Mexico for several years to continue work and research, before moving to Memphis, Tennessee and then Cincinnati.

MD: Case Western Reserve University, Cleveland, Ohio, 1977.

Residency: Rainbow Babies and Childrens, Cleveland, Ohio, 1979.

Fellowship: University Hospitals, Cleveland, Ohio, 1982.

Instructor:, Department of Neurology, University Hospitals, Cleveland, Ohio, 1983.

Fellowship: Epilepsy, National Institutes of Health, Bethesda, MD, 1983-1984.

Fellowship: Neurophysiology, National Institutes of Health, Bethesda, MD, 1984-1985.

Medical Staff Fellow: Clinical Epilepsy Section, National Institutes of Health, 1983-1984.

Medical Staff Fellow: EEG Laboratory, National Institutes of Health, 1984-1986.

Medical Staff Fellow: Unit on Neurophysiology, National Institutes of Health, 1986-1987.

Senior Staff Fellow: Unit on Neurophysiology, National Institutes of Health, 1987-1989.

Associate Professor: Department of Neurology, University of New Mexico, Albuquerque, NM, 1989-1992.

Director: Center for Magnetoencephalography, Albuquerque, NM, 1989-1992.

Associate Professor: Department of Pediatrics, University of Tennessee, Memphis, TN, 1992-2000.

Associate Professor: Department of Neurology, University of Tennessee, Memphis, TN, 1992-2000.

Adjunct Associate Professor: Memphis Speech and Hearing Center, Department of Audiology, University of Memphis, TN, 1998-present.

Division Chief: Child Neurology, Department of Pediatrics, University of Tennessee, 1994-2000.

Medical Director: Comprehensive Epilepsy Center, Le Bonheur Children's Medical, Center, Memphis, TN, 1992-2000.

Director: Cincinnati Children's Neurodiagnostic Laboratory, 2003 to present.

Director: Cincinnati Children's Clinical Neurophysiology Fellowship Program, 2001 to present.

Medical Director: Cincinnati Children's MEG Center, 2005 to present.

Certification: Pediatrics, 1984; Neurology with special competence in Child Neurology, 1984; Clinical Neurophysiology, 1986; Added Qualifications in Clinical Neurophysiology, 1994.

Practice Locations: Cincinnati Children's Hospital Medical Center Main Campus; Outpatient Services -- Anderson.

Mark Schapiro, MD Fetal and Neonatal Neurologist, Division of Neurology

is interested in identifying specific biomarkers for future neurological deficits, which may also serve as therapeutic targets in neonatal care. For example, premature newborns are at high risk for later neurological disorders due to disruption of normal brain development by prematurity, in association with ischemic and inflammatory injury in utero or in the perinatal period.

513-636-4222 mark.schapiro@cchmc.org

Brian J. Siroky, PhD Member, Division of Nephrology

focuses on understanding the mechanisms of renal cyst and tumor formation that occur in tuberous sclerosis complex (TSC), and identification of targeted therapies for these lesions. Structural and functional relationships between renal epithelial primary cilia (specialized cellular organelles whose dysfunction is linked to cystogenesis) and mTOR signaling, the pathway that is dysregulated in TSC is also an area of interest.

513-636-4497 brian.siroky@cchmc.org

Matthew R. Skelton, PhD Neurobiologist, Division of Neurology

is a neuroscientist who has a basic research program on the role of creatine in brain structure and function. The primary focus of his lab is the study of the mechanisms underlying intellectual disability caused by mutations in the creatine transporter gene.

Visit the Skelton Lab.

matthew.skelton@cchmc.org

High Res

Matthew R. Skelton, PhD

Neurobiologist, Division of Neurology

Academic Affiliations

Assistant Professor, UC Department of Pediatrics

Email matthew.skelton@cchmc.org

Show All

Visit the Skelton Lab.

BA: Biology, Bellarmine University, Louisville, KY, 2000.

PhD: Molecular and Developmental Biology, University of Cincinnati, Cincinnati, OH, 2006.

Vorhees CV, He E, Skelton MR, Graham DL, Schaefer TL, Grace CE, Braun AA, Amos-Kroohs R, Williams MT. Comparison of (+)-methamphetamine, ±-methylenedioxymethamphetamine, (+)-amphetamine and ±-fenfluramine in rats on egocentric learning in the Cincinnati water maze. Synapse. 2011 May;65(5):368-78.

Graham DL, Grace CE, Braun AA, Schaefer TL, Skelton MR, Tang PH, Vorhees CV, Williams MT. Effects of developmental stress and lead (Pb) on corticosterone after chronic and acute stress, brain monoamines, and blood Pb levels in rats. Int J Dev Neurosci. 2011 Feb;29(1):45-55.

Skelton MR, Schaefer TL, Graham DL, Degrauw TJ, Clark JF, Williams MT, Vorhees CV. Creatine transporter (CrT; Slc6a8) knockout mice as a model of human CrT deficiency. PLoS One. 2011 Jan 13;6(1):e16187.

Braun AA, Skelton MR, Vorhees CV, Williams MT. Comparison of the elevated plus and elevated zero mazes in treated and untreated male Sprague-Dawley rats: effects of anxiolytic and anxiogenic agents. Pharmacol Biochem Behav. 2011 Jan;97(3):406-15.

Grace CE, Schaefer TL, Graham DL, Skelton MR, Williams MT, Vorhees CV. Effects of inhibiting neonatal methamphetamine-induced corticosterone release in rats by adrenal autotransplantation on later learning, memory, and plasma corticosterone levels. Int J Dev Neurosci. 2010 Jun;28(4):331-42.

Grace CE, Schaefer TL, Herring NR, Graham DL, Skelton MR, Gudelsky GA, Williams MT, Vorhees CV. Effect of a neurotoxic dose regimen of (+)-methamphetamine on behavior, plasma corticosterone, and brain monoamines in adult C57BL/6 mice. Neurotoxicol Teratol. 2010 May-Jun;32(3):346-55.

Sun Y, Liou B, Ran H, Skelton MR, Williams MT, Vorhees CV, Kitatani K, Hannun YA, Witte DP, Xu YH, Grabowski GA. Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits. Hum Mol Genet. 2010 Mar 15;19(6):1088-97.

Sun Y, Ran H, Zamzow M, Kitatani K, Skelton MR, Williams MT, Vorhees CV, Witte DP, Hannun YA, Grabowski GA. Specific saposin C deficiency: CNS impairment and acid beta-glucosidase effects in the mouse. Hum Mol Genet. 2010 Feb 15;19(4):634-47.

Skelton MR, Schaefer TL, Herring NR, Grace CE, Vorhees CV, Williams MT. Comparison of the developmental effects of 5-methoxy-N,N-diisopropyltryptamine (Foxy) to (+/-)-3,4-methylenedioxymethamphetamine (ecstasy) in rats. Psychopharmacology(Berl). 2009 Jun;204(2):287-97.

Vorhees CV, Skelton MR, Grace CE, Schaefer TL, Graham DL, Braun AA, Williams MT. Effects of (+)-methamphetamine on path integration and spatial learning, but not locomotor activity or acoustic startle, align with the stress hyporesponsive period in rats. Int J Dev Neurosci. 2009 May;27(3):289-98.

Shannon M. Standridge, DO, MPH Co-Director, Rett Syndrome Clinic

is interested in the specific field of pediatric neurology, focusing on cost effective analyses. She seeks to understand the significance of healthcare savings and the magnitude of improvement in quality of life over an expected lifetime in young children undergoing epilepsy surgery.

513-636-4222 Shannon.Standridge@cchmc.org

High Res

Shannon M. Standridge, DO, MPH

Co-Director, Rett Syndrome Clinic

Epilepsy Specialist, Division of Neurology

Academic Affiliations

Assistant Professor, UC Department of Pediatrics

Phone 513-636-4222

Fax 513-636-1888

Email Shannon.Standridge@cchmc.org

Show All

Clinical Interests

General neurology

Fellowship: Neurophysiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2008; Neurology, Nationwide Children's Hospital, Columbus, OH, 2007.

Residency: Pediatrics, Nationwide Children's Hospital, Columbus, OH, 2004.

MPH: The Ohio State University College of Public Health, Columbus, OH, 2008.

DO: Kansas City University of Medicine and Biosciences, Kansas City, MO, 2002.

BS: Biology, Lyon College, Batesville, AS, 1997.

Standridge SM. Idiopathic intracranial hypertension in children: a review and algorithm. Pediatr Neurol. 2010 Dec;43(6):377-90.

Standridge SM, Holland KD, Horn PS. Cardiac arrhythmias and ictal events within an epilepsy monitoring unit. Pediatr Neurol. 2010 Mar;42(3):201-5.

Standridge SM, O'Brien SH. Idiopathic intracranial hypertension in a pediatric population: a retrospective analysis of the initial imaging evaluation. J Child Neurol. 2008 Nov;23(11):1308-11.

Mary Sutton, MD Pediatric Neuro-oncologist, Division of Neurology

513-636-4222

Cameron Thomas, MD, MS Fetal and Neonatal Neurology Specialist, Division of Neurology

is interested in understanding the effects of early life events such as seizures, medical procedures and pain on the developing brain.

513-636-4222 cameron.thomas@cchmc.org

Lubov Timchenko, PhD

investigates the molecular mechanisms of neuro-muscular and neuro-degenerative diseases myotonic dystrophy type 1, myotonic dystrophy type 2 and FXTAS. The major goal of her research is to develop therapeutic approaches for congenital and adult myotonic dystrophy.

513-803-0768 lubov.timchenko@cchmc.org

High Res

Lubov Timchenko, PhD

Academic Affiliations

Professor, UC Department of Pediatrics

Phone 513-803-0768

Email lubov.timchenko@cchmc.org

Show All

Clinical

Congenital myotonic dystrophy; adult myotonic dystrophy type 1; myotonic dystrophy type 2; FXTAS

Research

Molecular pathobiology and development of therapies for adult and congenital forms of neuro-muscular disease myotonic dystrophy type 1 and myotonic dystrophy type 2; the role of toxic RNAs containing long repeats in regulation of gene expression; skeletal muscle

Biography

Lubov Timchenko, PhD, is a professor in the UC Department of Pediatrics and a member of the Division of Neurology at Cincinnati Children’s Hospital Medical Center.

Dr. Lubov Timchenko received her PhD degree from St. Petersburg Institute of Experimental Medicine in St. Petersburg, Russia. She received post-doctoral training in molecular and human genetics at Baylor College of Medicine in Houston. Since 1995 until 2014, she was a faculty member at Baylor College of Medicine, working on the molecular mechanisms of neuro-muscular disorders, including myotonic dystrophy type 1 (DM1) and myotonic dystrophy type 2 (DM2).

In 2014, Dr. Timchenko joined the Department of Pediatrics at the University of Cincinnati and the Division of Neurology at Cincinnati Children's. Dr. Timchenko is internationally known for her contribution to several fundamental discoveries associated with the identification of a new family of RNA-binding proteins, CUGBP (also known as CUGBP and elav-like proteins, CELF), which play a significant role in the development and function of many tissues, including skeletal muscle, heart, brain and liver. Her studies showed that the proteins of this family regulate proliferation and differentiation in myogenesis and in liver cancer. The functional studies of the member of CUGBP protein family, CUGBP1, in myotonic dystrophy led to the discovery of a novel pathogenic mechanism by which non-coding RNAs cause neuro-muscular diseases. Recent work from Dr. Timchenko’s lab has suggested a new direction for therapy for adult and congenital myotonic dystrophy type 1.

Dr. Timchenko is a recipient of the prestigious Dr. Michael DeBakey’s Excellence in Research award for the outstanding contribution to biomedical research from Baylor College of Medicine. She has served on multiple national and international review boards at the National Institute of Arthritis, Skeletal Muscle and Skin Disorders, National Institute of Neurological Disorders and Stroke, Muscular Dystrophy Association, French Muscular Association, Italian Telethon and others.

PhD: St-Petersburg Institute of Experimental Medicine, St. Petersburg, Russia, 1983.

Post-doctoral training: Department of Molecular Genetics, Baylor College of Medicine, Houston, TX, 1992-1995.

Jones K, Wei C, Schoser B, Meola G, Timchenko N, Timchenko L. Reduction of toxic RNAs in Myotonic Dystrophies type 1 and type 2 by the RNA-helicase p68/DDX5. Proc Natl Acad Sci USA. 2015 Jun 30;112(26):8041-5.

Timchenko L. Molecular mechanisms of muscle atrophy in myotonic dystrophies. Int J Biochem Cell Biol. 2013 Oct;45(10):2280-7.

Wei C, Jones K, Timchenko NA, Timchenko L. GSK3 beta is a new therapeutic target for Myotonic Dystrophy type 1. Rare Dis. 2013 Sep 26;1:e26555.

Jones K, Wei C, Iakova P, Bugiardini E, Schneider-Gold C, Meola G, Woodgett J, Killian J, Timchenko NA, Timchenko LT. GSK3β mediates muscle pathology in myotonic dystrophy. J Clin Invest. 2012 Dec;122(12):4461-72.

Jones K, Jin B, Iakova P, Huichalaf C, Sarkar P, Schneider-Gold C, Schoser B, Meola G, Shyu AB, Timchenko N, Timchenko L. RNA Foci, CUGBP1, and ZNF9 are the primary targets of the mutant CUG and CCUG repeats expanded in myotonic dystrophies type 1 and type 2. Am J Pathol. 2011 Nov;179(5):2475-89.

Huichalaf C, Sakai K, Jin B, Jones K, Wang G-L, Schoser B, Schneider-Gold C, Sarkar P, Pereira-Smith OM, Timchenko N, Timchenko L. Expansion of CUG RNA repeats causes stress and inhibition of translation in Myotonic Dystrophy 1 cells. FASEB J. 2010;24:3706-3719.

Salisbury E, Schoser B, Schneider-Gold C, Wang GL, Huichalaf C, Jin B, Sirito M, Sarkar P, Krahe R, Timchenko NA, Timchenko LT. Expression of RNA CCUG repeats dysregulates translation and degradation of proteins in DM2 patients. Am J Pathol. 2009 Aug;175(2):748-62.

Huichalaf C, Schoser B, Schneider-Gold C, Jin B, Sarkar P, Timchenko L. Reduction the rate of protein translation in patients with Myotonic Dystrophy 2. J Neurosci. 2009 Jul 15;29(28):9042-9.

Philips AV, Timchenko LT, Cooper TA. Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. Science. 1998;280:737-440.

Lu X, Timchenko NA, Timchenko LT. Cardiac elav-type RNA-binding protein (ETR-3) binds to RNA CUG repeats expanded in myotonic dystrophy. Hum Mol Genet. 1999;8:53-60.

Grants

Myotonic Dystrophy type 2. Principal Investigator. National Institutes of Health - National Institute of Arthritis and Musculoskeletal and Skin Diseases. 2005-2016.

Inhibition of GSK3 beta as potential therapy for DM1. Principal Investigator. National Institutes of Health - National Institute of Arthritis and Musculoskeletal and Skin Diseases. 2014-2016.

The toxicity of the RNA CGG repeats in FXTAS. Principal Investigator. National Institutes of Health - National Institute of Neurological Disorders and Stroke. 2013-2016.

Developmental fund. Principal Investigator. Cincinnati Children’s Hospital. 2014-2019.

Jennifer J. Vannest, PhD Director, Pediatric Neuroimaging Research Consortium

is interested in the use of functional MRI and behavioral testing to examine how epilepsy and neurodevelopmental disorders affect language function and the brain circuitry that supports it. The goal of these studies is to provide better treatment and educational strategies for children with these disorders.

513-636-6959 jennifer.vannest@cchmc.org

High Res

Jennifer J. Vannest, PhD

Director, Pediatric Neuroimaging Research Consortium

Academic Affiliations

Associate Professor, UC Department of Pediatrics

Phone 513-636-6959

Email jennifer.vannest@cchmc.org

Show All

Clinical

Cognitive neuroscience of language and memory (using functional MRI); cognitive effects of epilepsy and neurodevelopmental disorders

Research

Neurological disorders and language impairments

Biography

Jennifer Vannest, PhD, completed her undergraduate education at the Ohio State University and continued there for her graduate work. Her PhD is in linguistics, and in addition, her graduate training included a number of courses in cognitive psychology, neuropsychology and speech and hearing sciences. As a postdoctoral fellow at University of Michigan and University of Rochester, Dr. Vannest was trained to use functional MRI to study the brain mechanisms underlying language skill.

Dr. Vannest came to Cincinnati Children's Hospital Medical Center in 2006, and her current research makes use of functional MRI to examine how epilepsy and neurodevelopmental disorders affect language function, ultimately leading to better treatment and educational strategies for children with these disorders.

PhD: Linguistics, Ohio State University, Columbus, OH.

Postdoctoral Training: Psychology, University of Michigan, Ann Arbor, MI; Brain and Cognitive Sciences, University of Rochester, Rochester, NY.

Vannest J, Newport EL, Newman AJ, Bavelier D. Interplay between morphology and frequency in lexical access: The case of the base frequency effect. Brain Res. 2011 Feb 10;1373:144-59.

Korostenskaja M, Pardos M, Fujiwara H, Kujala T, Horn P, Rose D, Byars A, Brown D, Seo JH, Wang Y, Vannest J, Xiang J, Degrauw T, Näätänen R, Lee KH. Neuromagnetic evidence of impaired cortical auditory processing in pediatric intractable epilepsy. Epilepsy Res. 2010 Nov;92(1):63-73.

Vannest J, Rasmussen J, Eaton KP, Patel K, Schmithorst V, Karunanayaka P, Plante E, Byars A, Holland S. FMRI activation in language areas correlates with verb generation performance in children. Neuropediatrics. 2010 Oct;41(5):235-9.

Szaflarski JP, Eaton K, Ball AL, Banks C, Vannest J, Allendorfer JB, Page S, Holland SK. Poststroke Aphasia Recovery Assessed With Functional Magnetic Resonance Imaging and a Picture Identification Task. J Stroke Cerebrovasc Dis. 2010 Aug 17.

Karunanayaka P, Schmithorst VJ, Vannest J, Szaflarski JP, Plante E, Holland SK. A group independent component analysis of covert verb generation in children: a functional magnetic resonance imaging study. NeuroImage. 2010 May 15;51(1):472-87.

Vannest J, Karunanayaka PR, Schmithorst VJ, Szaflarski JP, Holland SK. Language networks in children: evidence from functional MRI studies. AJR Am J Roentgenol. 2009 May;192(5):1190-6.

Vannest JJ, Karunanayaka PR, Altaye M, Schmithorst VJ, Plante EM, Eaton KJ, Rasmussen JM, Holland SK. Comparison of fMRI data from passive listening and active-response story processing tasks in children. J Magn Reson Imaging. 2009 Apr;29(4):971-6.

Wang Y, Xiang J, Kotecha R, Vannest J, Liu Y, Rose D, Schapiro M, Degrauw T. Spatial and frequency differences of neuromagnetic activities between the perception of open- and closed-class words. Brain Topogr. 2008 Dec;21(2):75-85.

Liu Y, Xiang J, Wang Y, Vannest JJ, Byars AW, Rose DF. Spatial and frequency differences of neuromagnetic activities in processing concrete and abstract words. Brain Topogr. 2008 Spring;20(3):123-9.

Vannest J, Szaflarski JP, Privitera MD, Schefft BK, Holland SK. Medial temporal fMRI activation reflects memory lateralization and memory performance in patients with epilepsy. Epilepsy Behav. 2008 Apr;12(3):410-8.

Marissa M. Vawter, MD

513-636-4214 marissa.vawter@cchmc.org

Charu Venkatesan, MD, PhD Fetal and Neonatal Neurology Specialist, Division of Neurology

has interests and expertise in conditions affecting the neonatal brain such as seizures, hypoxic ischemic injury, intracranial hemorrhage and brain malformations. Her research includes understanding mechanisms by which the neonatal brain responds to injury and how endogenous repair processes can be improved.

513-636-4222 charulata.venkatesan@cchmc.org

High Res

Charu Venkatesan, MD, PhD

Fetal and Neonatal Neurology Specialist, Division of Neurology

Academic Affiliations

Assistant Professor, UC Department of Pediatrics

Phone 513-636-4222

Email charulata.venkatesan@cchmc.org

Show All

Clinical

Pediatric neurology; fetal neurology; neonatal neurology

Research

Neonatal brain injury

BA: Columbia University, NY, NY, 1992.

PhD: State University of NY at Stony Brook, Stony Brook, NY, 2000.

MD: State University of NY at Stony Brook, Stony Brook, NY, 2002.

Residency: Pediatrics, Northwestern University, Chicago, IL, 2004.

Residency: Child Neurology, Northwestern University, Chicago, IL, 2007.

Certification: Neurology with Special Qualifications in Child Neurology, 2008.

Venkatesan C, Krueger JM, Millichap JJ, Nangia S, Ritacco D, Stack C, Nordli DR. Epilepsy Following Neonatal Seizures Secondary to Hemorrhagic Stroke in Term Neonates. Journal of Child Neurology. 2015 Aug 24.

Cirillo M, Venkatesan C, Millichap JJ, Stack CV, Nordli DR. Case Report: Case Report: Intravenous and Oral Pyridoxine Trial for Diagnosis of Pyridoxine-Dependent Epilepsy. Pediatrics. 2015;2014-2423.

Jung D, Ritacco D, Nordli DR, Koh S, Venkatesan C. Early anatomical injury patterns predict epilepsy in head cooled neonates with hypoxic ischemic encephalopathy. Pediatr Neurol. 2015;S0887-8994(15)00218-0.

Venkatesan C, Birch D, Peng CY, Kessler JA. Astrocytic 1-integrin affects cellular composition of murine blood brain barrier in the cerebral cortex. Int J Dev Neurosci. 2015 May 19;44:48-54.

Krueger J, Piantino J, Smith C, Angle B, Venkatesan C, Wainwright M. A treatable metabolic cause of encephalopathy: Cobalamin C defect in an eight year old male. Pediatrics. 2015;135(1):202-206.

Rossi JL, Ralay Ranaivo H, Patel F, Chrzaszcz M, Venkatesan C, Wainwright MS. Albumin causes increased myosin light chain kinase expression in astrocytes via p38 mitogen-activated protein kinase. Journal of Neuroscience Research. 2011;89(6):852-61.

Chrzaszcz M, Venkatesan C, Dragisic T, Watterson DM, Wainwright M. Minozac treatment prevents increased seizure susceptibility in a mouse 'two-hit' model of closed skull traumatic brain injury and electroconvulsive shock-induced seizures. J Neurotrauma. 2010;27(&):1283-95.

Venkatesan C, Chrzaszcz M, Choi N, Wainwright MS. Chronic upregulation of activated microglia immunoreactive for galectin-3/Mac-2 and nerve growth factor following diffuse axonal injury. J Neuroinflammation. 2010;7(1):32.

Venkatesan C, Wainwright M. Pediatric endocarditis and stroke: a single center retrospective review of seven cases. Pediatric Neurology. 2008;38(3):243-7.

Venkatesan C, Kritzer MF. Perinatal gonadectomy affects corticocortical connections in motor but not visual cortex in adult male rats. Journal of Comparative Neurology. 1999;415:240-265.

Charles V. Vorhees, PhD Co-Director, Animal Behavior Core

focuses on how drugs, genes, immune activators and environmental agents adversely affect the developing brain, along with Dr. Michael Williams. Projects range from early stress to prenatal exposure to drugs of abuse, from creatine transporter deficiency to genes associated with depression, and from lead-manganese toxicity to autism. The overarching interest is on developmental origins of nervous system disorders, particularly those originating prenatally using behavioral, neurochemical, immunohistochemical, pharmacological and genetic methods.
Visit the Vorhees/Williams Lab.

513-636-8622 charles.vorhees@cchmc.org

High Res

Charles V. Vorhees, PhD

Co-Director, Animal Behavior Core

Academic Affiliations

Professor, UC Department of Pediatrics

Phone 513-636-8622

Fax 513-636-3912

Email charles.vorhees@cchmc.org

Show All

Specialties

Visit the Vorhees-Williams Lab.

Principal areas of investigation are how drugs, genetic mutations, environmental agents, and stressors affect prenatal and neonatal brain development and behavior. The lab is particularly interested in the long-term effects of such perturbations on cognitive development.

Biography

Visit the Animal Behavioral Core.

Dr. Vorhees came to Cincinnati Children’s in 1976 as a postdoctoral research scholar and was recruited to the faculty in 1978 as assistant professor within the University of Cincinnati College of Medicine. He was promoted to associate professor in 1982, tenured in 1984, and promoted to professor in 1988 with primary appointment in pediatrics and joint appointment in environmental health. He is co-director of the Animal Behavior Core and program director of the Teratology Training Program. He is on the graduate faculty of the Graduate Programs in Neuroscience (NS) and Molecular and Developmental Biology (MDB). He is section editor of the journal Neurotoxicology and Teratology and served as editor-in-chief for nine years. He was director of the MDB Graduate Program for six years and served in other leadership positions for 15 years. Dr. Vorhees has also served in leadership positions in the NS Program and is currently a member of the Admissions Committee. Dr. Vorhees has been extramurally funded for 35 years, receiving grants from NIH, NSF, FDA and other agencies. He holds an NIH T32 training grant funded for years 36-40 through 2017. He is a founding member of the Neurobehavioral Teratology Society in 1977 and was elected president in 1984-85 and 2012-13. He is an elected member of Sigma Xi, an Eli Lilly Distinguished Lecturer in 1990, and a Society for Neuroscience Grass Foundation Lecturer in 2002. Dr. Vorhees has served on multiple FDA, NRC, and EPA advisory panels. He has been an NIH grant reviewer on varies committees for more than 26 years. He has also reviewed grants for NSF, VA, EPA; March of Dimes, and other agencies and foundations in the U.S.; and for funding agencies in Israel, Ireland, Great Britain, and New Zealand. His research focuses on brain development and behavior. As of 2013 he has published than more 276 journal articles and book chapters.

Visit the Vorhees Lab.

MA: Neurobiology Program, Vanderbilt University, Nashville, TN, 1973.

PhD: Neurobiology Program, Vanderbilt University, Nashville, TN, 1976.

Hautman ER, Williams MT, Vorhees CV, Skelton MR. Female mice heterozygous for creatine transporter deficiency show moderate cognitive deficits. J Inherited Metab Dis. 2014 Jan;37(1):63-8.

Sun Y, Zamzow M, Ran H, Zhang W, Quinn B, Barnes S, Witte DP, Setchell KDR, Williams MT, Vorhees CV, Grabowski GA. Tissue-specific effects of saposin A and saposin B on glycosphingolipids degradation in mutant mice. Hum Mol Genet. 2013 Jun 15;22(12):2435-50.

Amos-Kroohs RM, Williams MT, Braun AA, Graham DL, Webb CL, Birtles TS, Greene RM, Vorhees CV, Pisano MM. Neurobehavioral phenotype of C57BL/6J mice prenatally and neonatally exposed to cigarette smoke. Neurotoxicol Teratol. 2013;35, 34-45.

Schaefer TL, Grace CE, Braun AA, Amos-Kroohs RM, Graham DL, Skelton MR, Williams MT, Vorhees CV. Cognitive impairments from developmental exposure to serotonergic drugs: citalopram or MDMA. Int J Neuropsychopharmacol. 2013;16, 1383-94.

Graham DL, Amos-Kroohs RM, Braun AA, Grace CE, Schaefer TL, Skelton MR, Vorhees CV, Williams MT. Neonatal (+)-methamphetamine exposure in rats alters adult locomotor responses to dopamine D1 and D2 agonists and to a glutamate NMDA receptor antagonist, but not to serotonin agonists. Int J Neuropsychopharmacol. 2012;16, 377-391.

Vorhees CV, Graham DL, Braun AA, Schaefer TL, Skelton MR, Richtand NM, Williams MT. Prenatal immune challenge in rats: Altered responses to dopaminergic and glutamatergic agents, prepulse inhibition of acoustic startle, and reduced route-based learning as a function of maternal body weight gain after prenatal exposure to Poly IC. Synapse. 2012;66(8), 725-737.

Schaefer TL, Braun AA, Amos-Kroohs RM, Williams MT, Ostertag E, Vorhees CV. A new model of Pde4d deficiency: Genetic knock-down of PDE4D enzyme in rats produces an antidepressant phenotype without spatial cognitive effects. Genes Brain Behav. 2012;11(5), 614-622.

Chen Y, Curran CP, Nebert DW, Patel KV, Williams MT, Vorhees CV. Effect of chronic glutathione deficiency on the behavioral phenotype of Gclm(-/-) knockout mice. Neurotoxicol Teratol. 2012;34, 450-457.

Skelton MR, Graham DL, Schaefer TL, Grace CE, Braun AA, Burns LA, Amos-Kroohs RM, Williams MT, Vorhees CV. Distinct periods of developmental sensitive to the effects 3,4-(±)-methylenedioxymethamphetamine (MDMA) on behaviour and monoamines in rats. Int J Neuropsychopharmacol. 2012;15, 811-824.

Braun AA, Graham DL, Schaefer TL, Vorhees CV, Williams MT. Dorsal striatal dopamine depletion impairs both allocentric and egocentric navigation in rats. Neurobiol Learn Mem. 2012;97(4), 402-408.

Grants

Transgenerational inheritance of epigenetic effects of polychlorinated biphenyls. Co-Principal Investigator. National Institutes of Health. 2013-2016.

Training Grant in Teratology. Principal Investigator. National Institutes of Health. 2012-2017.

Kris R. Wesselkamper, MD Neurohospitalist, Division of Neurology

is interested in including quality improvement, safety and standardization of care for patients with neurologic conditions who are admitted to the hospital.

513-636-4222 kris.wesselkamper@cchmc.org

Michael T. Williams, PhD Co-Director, Animal Behavior Core

focuses on how drugs, genes, immune activators and environmental agents adversely affect the developing brain, along with Dr. Charles Vorhees. Projects range from early stress to prenatal exposure to drugs of abuse, from creatine transporter deficiency to genes associated with depression, and from lead-manganese toxicity to autism. The overarching interest is on developmental origins of nervous system disorders, particularly those originating prenatally using behavioral, neurochemical, immunohistochemical, pharmacological and genetic methods.
Visit the Vorhees/Williams Lab.

513-636-8624 michael.williams@cchmc.org

High Res

Michael T. Williams, PhD

Co-Director, Animal Behavior Core

Academic Affiliations

Associate Professor, UC Department of Pediatrics

Phone 513-636-8624

Fax 513-636-3912

Email michael.williams@cchmc.org

Show All

Visit the Vorhees-Williams Lab.

AA: Psychology, Belleville Area College, Belleville, IL.

BS: Psychology, Wright State University, Dayton, OH.

PhD: Biomedical Sciences, Wright State University, Dayton, OH.

Postdoctoral Fellow: Psychoneuroimmunology, Ohio State University, Columbus, OH.

Postdoctoral Fellow: Teratology, Children's Hospital Research Foundation.

Skelton MR, Schaefer TL, Graham DL, Degrauw TJ, Clark JF, Williams MT, Vorhees CV. Creatine Transporter (CrT; Slc6a8) Knockout Mice as a Model of Human CrT Deficiency. PLoS One. 2011 Jan 13;6(1):e16187.

Curran CP, Vorhees CV, Williams MT, Genter MB, Miller ML, Nebert DW. In utero and lactational exposure to a complex mixture of polychlorinated biphenyls: toxicity in pups dependent on the Cyp1a2 and Ahr genotypes. Toxicol Sci. 2011 Jan;119(1):189-208.

Graham DL, Grace CE, Braun AA, Schaefer TL, Skelton MR, Tang PH, Vorhees CV, Williams MT. Effects of developmental stress and lead (Pb) on corticosterone after chronic and acute stress, brain monoamines, and blood Pb levels in rats. Int J Dev Neurosci. 2011 Feb;29(1):45-55.

Braun AA, Skelton MR, Vorhees CV, Williams MT. Comparison of the elevated plus and elevated zero mazes in treated and untreated male Sprague-Dawley rats: effects of anxiolytic and anxiogenic agents. Pharmacol Biochem Behav. 2011 Jan;97(3):406-15.

Schaefer TL, Grace CE, Gudelsky GA, Vorhees CV, Williams MT. Effects on plasma corticosterone levels and brain serotonin from interference with methamphetamine-induced corticosterone release in neonatal rats. Stress. 2010 Nov;13(6):469-80.

Herring NR, Gudelsky GA, Vorhees CV, Williams MT.(+)-Methamphetamine-induced monoamine reductions and impaired egocentric learning in adrenalectomized rats is independent of hyperthermia. Synapse. 2010 Oct;64(10):773-85.

Schaefer TL, Lingrel JB, Moseley AE, Vorhees CV, Williams MT. Targeted mutations in the Na,K-ATPase alpha 2 isoform confer ouabain resistance and result in abnormal behavior in mice. Synapse. 2010 Oct 8.

Vorhees CV, He E, Skelton MR, Graham DL, Schaefer TL, Grace CE, Braun AA, Amos-Kroohs R, Williams MT. Comparison of (+)-methamphetamine, ±-Methylenedioxymethamphetamine, (+)-amphetamine and ±-fenfluramine in rats on egocentric learning in the Cincinnati water maze. Synapse. 2010 Aug 20.

Grace CE, Schaefer TL, Graham DL, Skelton MR, Williams MT, Vorhees CV. Effects of inhibiting neonatal methamphetamine-induced corticosterone release in rats by adrenal autotransplantation on later learning, memory, and plasma corticosterone levels. Int J Dev Neurosci. 2010 Jun;28(4):331-42.

Zhu H, Mingler MK, McBride ML, Murphy AJ, Valenzuela DM, Yancopoulos GD, Williams MT, Vorhees CV, Rothenberg ME. Abnormal response to stress and impaired NPS-induced hyperlocomotion, anxiolytic effect and corticosterone increase in mice lacking NPSR1. Psychoneuroendocrinology. 2010 Sep;35(8):1119-32.

Brenda Wong, MD, MBBS Director, Comprehensive Neuromuscular Center/MDA Clinic

focuses on neuromuscular disorders in children including clinical research in Duchenne muscular dystrophy and spinal muscular atrophy and genomics in DMD and NM disorders.

513-636-4222 brenda.wong@cchmc.org

High Res

Brenda Wong, MD, MBBS

Director, Comprehensive Neuromuscular Center/MDA Clinic

Academic Affiliations

Professor, UC Department of Pediatrics

UC Department of Neurology and Rehabilitation Medicine

Phone 513-636-4222

Fax 513-636-3980

Email brenda.wong@cchmc.org

Show All

Clinical Interests

Neuromuscular disorders

Biography

After medical school, Brenda Wong, MD, received training in general pediatrics and worked as a pediatrician for a few years before doing her three-year child neurology fellowship at Cincinnati Children's Hospital Medical Center.

Dr. Wong also received training in pediatric neuromuscular disorders at Hammersmith Hospital, London with Dr. Victor Dubowitz and Dr. Francesco Muntoni. Dr. Wong's training in EMGs was accomplished with Dr. John Quinlan in the Department of Neurology at the University of Cincinnati.

Post fellowship training, Dr. Wong was practicing child neurology in private practice prior to joining Cincinnati Children's in 1999.

Besides general neurology patients, Dr. Wong sees patients with neuromuscular disorders in the Neuromuscular Clinic and provide diagnostic services like EMGs and evaluation for muscle biopsies. Comprehensive management is supported by the Division of Rehabilitative Medicine, Pulmonary Medicine, Pediatric Orthopedics and the Muscular Dystrophy Association.

MD: University of Singapore, 1980.

Residency: University Department of Pediatrics, Singapore, 1981, 1984-85; Royal Hospital for Sick Children, Edinburgh, 1985-88.

Fellowship: Child Neurology, Children's Hospital Medical Center, Cincinnati, OH, 1994-97; Neuromuscular Disorders, Hammersmith Hospital, London, 1997.

Certification: Child Neurology, 1998.

Miles MV, Putnam PE, Miles L, Tang PH, DeGrauw AJ, Wong BL, Horn PS, Foote HL, Rothenberg ME. Acquired coenzyme Q10 deficiency in children with recurrent food intolerance and allergies. Mitochondrion. 2011 Jan;11(1):127-35.

Kim HK, Laor T, Horn PS, Racadio JM, Wong B, Dardzinski BJ. T2 mapping in Duchenne muscular dystrophy: distribution of disease activity and correlation with clinical assessments. Radiology. 2010 Jun;255(3):899-908.

Kim HK, Laor T, Horn PS, Wong B. Quantitative assessment of the T2 relaxation time of the gluteus muscles in children with Duchenne muscular dystrophy: a comparative study before and after steroid treatment. Korean J Radiol. 2010 May-Jun;11(3):304-11.

Yang Z, Funke BH, Cripe LH, Vick GW 3rd, Mancini-Dinardo D, Peña LS, Kanter RJ, Wong B, Westerfield BH, Varela JJ, Fan Y, Towbin JA, Vatta M. LAMP2 microdeletions in patients with Danon disease Circ Cardiovasc Genet. 2010 Apr;3(2):129-37.

Henderson RC, Berglund LM, May R, Zemel BS, Grossberg RI, Johnson J, Plotkin H, Stevenson RD, Szalay E, Wong B, Kecskemethy HH, Harcke HT. The relationship between fractures and DXA measures of BMD in the distal femur of children and adolescents with cerebral palsy or muscular dystrophy. J Bone Miner Res. 2010 Mar; 25(3):520-6.

Steve W. Wu, MD Medical Director, Dystonia Clinic

is interested in pediatric movement disorders, including Tourette syndrome. He is also actively involved in transcranial magnetic stimulation research.
Visit the Gilbert / Wu / Pedapati Lab.

513-636-4222 steve.wu@cchmc.org

High Res

Steve W. Wu, MD

Medical Director, Dystonia Clinic

Academic Affiliations

Assistant Professor, UC Department of Pediatrics

Phone 513-636-4222

Email steve.wu@cchmc.org

Show All

Visit the Gilbert / Wu / Pedapati Lab.

Clinical

Pediatric neurology with specialty in pediatric movement disorder; botulinum toxin (Botox) injection for dystonia, spasticity, tics; deep brain stimulation (DBS)

Research

Neuroplasticity; movement disorders; transcranial magnetic stimulation (TMS); transcranial direct current stimulation (tDCS)

Biography

Dr. Steve Wu is a pediatric neurologist with interests in children with movement disorders. Drs. Wu, Gilbert (Neurology) and Vadivelu (Neurosurgery) also work together in the Dystonia/Deep Brain Stimulation Clinic to care for children/adolescents with dystonia and complex movement disorders.

Dr. Wu’s research interest focuses on movement disorders and neuroplasticity of the brain. Dr. Wu collaborates with Dr. Donald Gilbert in the Transcranial Magnetic Stimulation Lab at Cincinnati Children’s Hospital Medical Center.

BA: University of California, Berkeley, CA, 1997.

MD: Vanderbilt University, Nashville, TN, 2003.

Residency: Pediatrics and Pediatric Neurology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2003-2008.

Fellowship: Pediatric Movement Disorders, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2008-2009.

Pedapati EV, Gilbert DL, Horn PS, Huddleston DA, Laue CS, Shahana N, Wu SW. Effect of 30 Hz Theta Burst Transcranial Magnetic Stimulation on the Primary Motor Cortex in Children and Adolescents. Front Hum Neurosci. 2015;9:91.

Wu SW, Gilbert DL. Measuring neuroplasticity in children using brain stimulation (Commentary). Dev Med Child Neurol. 2015.

Hong YH, Wu SW, Pedapati EV, Horn PS, Huddleston DA, Laue CS, Gilbert DL. Safety and Tolerability of Theta Burst Stimulation versus Single and Paired Pulse Transcranial Magnetic Stimulation: A Comparative Study of 165 Pediatric Subjects. Front Hum Neurosci. 2015.

Chen TH, Wu SW, Dixon S, Shahana N, Huddleston DA, Sarvis AR, Sallee FR, Gilbert DL. Reduced short interval cortical inhibition correlates with atomoxetine response in children with attention-deficit hyperactivity disorder (ADHD). J Child Neurol. 2014;29:1672-9.

Wu SW, Maloney T, Gilbert DL, Dixon SG, Horn PS, Huddleston DA, Eaton K, Vannest J. Functional MRI-navigated Repetitive Transcranial Magnetic Stimulation over Supplementary Motor Area in Chronic Tic Disorders. Brain Stimulation. 2014;7(2):212–218.

Hedera P, Xiao J, Puschmann A, Momčilović D, Wu SW, LeDoux MS. Novel PRRT2 mutation in an African-American family with paroxysmal kinesigenic dyskinesia. BMC Neurology. 2012;12:93.

Klotz J, Johnson M, Wu SW, Isaacs KM, Gilbert DL. Relationship between Reaction Time Variability and Motor Skill Development in ADHD. Child Neuropsychology. 2012;18:576-585.

Wu SW, Gilbert DL, Shahana N, Huddleston DA, Mostofsky SH. Transcranial Magnetic Stimulation Measures in Attention-Deficit/Hyperactivity Disorder. Pediatric Neurology. 2012;47:177-185.

Wu SW, Shahana N, Huddleston DA, Gilbert DL. Effects of 30 Hz Theta Burst Transcranial Magnetic Stimulation on the Primary Motor Cortex. Journal of Neuroscience Methods. 2012;208:161-164.

Wu SW, Shahana N, Huddleston DA, Lewis AN, Gilbert DL. Safety and Tolerability of Theta-Burst Transcranial Magnetic Stimulation in Children. Developmental Medicine and Child Neurology. 2012;54:636-639.

Jing Xiang, MD, PhD Director of MEG Research, Division of Neurology

focuses on the identification of pathological HFBS in epilepsy, migraine and other brain disorders. Dr. Xiang is currently building on recent discoveries that the brain generates high-frequency brain signals (HFBS, ~2,632 Hz) and that magnetoencephalography (MEG) can detect HFBS noninvasively.
Visit the Xiang Lab.

513-636-4222 jing.xiang@cchmc.org

High Res

Jing Xiang, MD, PhD

Director of MEG Research, Division of Neurology

Academic Affiliations

Associate Professor, UC Department of Pediatrics

Phone 513-636-4222

Fax 513-636-1888

Email jing.xiang@cchmc.org

Show All

Clinical

Epilepsy and pre-operative functional mapping

Research

Visit the Xiang Lab.

MD: Postgraduate Medical School, Beijing, China, 1994.

PhD: The Graduate University for Advanced Studies, Okazaki, Japan, 1998.